Introduction {#S1}
============

Echocardiography represents a gold standard for the assessment of patients with systolic heart failure (HF) and most of clinical and therapeutic decisions are based on the values of left ventricular ejection fraction (LVEF) obtained through this technique. The current guidelines indicate a LVEF ≤ 35% as the cut off value to identify patients at higher risk of HF progression and sudden death ([@B28]). However, less than one third of implantable cardioverter defibrillator (ICD) recipients in primary prevention receives appropriate therapy, thus suggesting as a reduced LVEF could not always be associated to an arrhythmogenic substrate ([@B32]). Furthermore, although LVEF undoubtedly represents an important prognostic risk marker, in many cases it cannot express all the complex metabolic and neurohormonal alterations associated with HF prognosis. Recent evidence highlight the role of epicardial adipose tissue (EAT) in HF pathogenesis and progression ([@B26]; [@B22]; [@B1]). We have previously reported that EAT is increased in patients with systolic HF and may concur to HF-related cardiac adrenergic derangement being a local source of catecholamines ([@B26]). Furthermore, an EAT pro-inflammatory phenotype can affect the electrophysiological properties of myocytes and induce fibrosis, thus promoting arrhythmogenesis and HF progression ([@B15]; [@B20]).

Although several evidence support the pathophysiological implication of EAT in HF, the prognostic value of EAT accumulation in HF patients is still unknown. To this aim, in the present study, we explored the predictive value of echocardiographic EAT thickness on clinical and arrhythmic outcomes of a high-risk HF population.

Materials and Methods {#S2}
=====================

Study Population {#S2.SS1}
----------------

The study population included 69 consecutive patients with systolic HF referred to ICD implantation for primary or secondary prevention, recruited at the HF clinic of Federico II University of Naples, in accordance to the current HF guidelines of the European Society of Cardiology ([@B28]). The inclusion criteria were: (i) patients enrolled for ICD implantation in primary prevention, defined as symptomatic HF patients (NYHA Class II--III) with a LVEF ≤35% despite ≥3 months of optimal medical therapy, and without acute coronary syndromes in the last 3 months; (ii) patients enrolled for ICD implantation in secondary prevention, defined as patients who have recovered from a ventricular arrhythmia causing haemodynamic instability, and who were expected to survive more than one year with good functional status. We excluded patients with conditions known to interfere with systemic and local EAT inflammation and associated to EAT thickness increase such as moderate to severe valvular disease, chronic atrial fibrillation, myocardial inflammatory diseases, cancer and or systemic inflammatory diseases.

At the time of enrolment and before ICD implantation, all patients underwent a complete clinical examination. Demographic data, including age, sex, HF medications, cardiovascular risk factors and the presence of comorbidities were also collected.

The study was approved by the local Ethics Committee. All procedures performed in the study were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and conformed to the Declaration of Helsinki on human research. All patients included in the study gave written informed consent after receiving an accurate explanation of the study protocol and of the potential risks related to the procedures adopted by the study.

Echocardiographic Study {#S2.SS2}
-----------------------

All patients underwent a complete echocardiographic examination including EAT measurement. Echocardiograms were performed by a VIVID E9 (GE Healthcare) machine, according to standard techniques. EAT thickness was obtained, as previously described ([@B24]). EAT was visualized in parasternal long-axis view between the free wall of the right ventricle and the anterior surface of the ascending aorta. To improve image quality, the depth was reduced, the focus adjusted, and ultrasound beam frequency slightly increased. The colorimetric map was switched into gold. Once visualized the EAT deposit, the maximum EAT thickness was measured at end-systole ([Figure 1](#F1){ref-type="fig"}). The average value from 3 cardiac cycles was used for the statistical analysis.

![EAT thickness visualization and measurement in parasternal long axis view; panel **(A)** thin epicardial adipose tissue; panel **(B)** thick epicardial adipose tissue. EAT, Epicardial Adipose Tissue; LA, left atrium; LV, left ventricle; Ao, ascending aorta; RV, right ventricle. EAT is visualized between the visceral layer of the pericardium an the myocardium at the Rindfleisch fold.](fphys-11-00043-g001){#F1}

Follow Up and Outcomes {#S2.SS3}
----------------------

All patients underwent a 6-month follow-up. At any follow-up visit, patients underwent clinical examination and ICD check. We considered a composite clinical and arrhythmic outcome including HF related deaths, new hospital admissions for HF worsening, and atrial and ventricular arrhythmic events (atrial tachycardia and/or atrial fibrillation lasting more than 30 s, ventricular tachycardia lasting more than 8 beats and episodes of ventricular fibrillation, shock-treated or self-terminating). Clinical and arrhythmic outcomes were also evaluated separately.

Statistical Analysis {#S2.SS4}
--------------------

Numerical variables were described using mean ± standard deviation with range while categorical factors were synthetized using absolute frequencies and percentages. Baseline correlations among clinical and demographical characteristics were estimated using the Pearson correlation coefficient. Events free survival was defined as the time between and the first occurrence of any of the cardiovascular events assessed in the present study (arrhythmic, clinical or both) or censoring, whichever occurred first. Incidence rates were estimated using the cumulative time at risk at denominator and the number of patients with at least one event as numerator. The corresponding 95% confidence intervals (95% C.I) were computed assuming a Poisson distribution. The association between EAT, LVEF and the risk of cardiovascular events was assessed using univariate and multivariable Cox regression while the cumulative probability of events was estimated, and graphically represented, using the Kaplan--Meier method. Statistical significance was accepted at *p* \< 0.05.

Results {#S3}
=======

[Table 1](#T1){ref-type="table"} illustrates demographic, clinical, and echocardiographic data of the whole population. The mean age was 64.5 ± 10.4 (range 40--90) years and 88.4% of patients were men.

###### 

Demographic and clinical data of the study population.

                                                   **Overall cohort (n. 69 pts)**
  ------------------------------------------------ --------------------------------
  Age, yrs                                         64.5 ± 10 (40--90)
  Gender, Male, n (%)                              61 (88.4)
  NYHA class (%)                                   --
   I                                               2 (2.9)
   II                                              46 (66.7)
   III                                             21 (30.4)
  **Cardiovascular risk factors**                  
  Smokers, n (%)                                   43 (63.2)
  Diabetes, n (%)                                  36 (52.2)
  Hypertension, n (%)                              47 (68.1)
  Dyslipidemia, n (%)                              48 (69.6)
  Ischemic cause of HF, n (%)                      47 (68.1)
  Echocardiographic EAT thickness (mm) mean ± SD   10.2 ± 3.6 (4 to 20)
  LVEF (%), mean ± SD                              35.7 ± 7.8 (20 to 64)
  LVEF ≤ 35%, n (%)                                36 (52.9)
  **HF drug therapy**                              
  Beta blockers, n (%)                             52 (75.4)
  ACE I/ARB, n (%)                                 54 (78.6)
  Aldosterone antagonists                          31 (44.9)

NYHA, New York heart association; HF, heart failure; EAT, epicardial adipose tissue; LVEF, left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.

Most of patients were in NYHA class II (66.7%) and III (30.4%). Ischemic cause of HF was recognized in 47.1% of cases. Fifty-two percent of patients were diabetics, 68.1% had hypertension, 63.2% were smokers, and 69.6% had dyslipidaemia. Most of patients were on optimal HF drug therapy. Mean LVEF was 35.7 ± 7.8%, and was ≤ 35% in 52.9% of patients. Mean EAT thickness was 10.2 ± 3.6 (range: 4--20) mm.

Epicardial adipose tissue thickness did not correlate with LVEF (*r* = −0.11, *p* = 0.369), whereas it showed a significant correlation with age (*r* = 0.25, *p* = 0.037) and left atrial volume (*r* = 0.29. *p* = 0.027). EAT thickness was not associated with diabetes (*p* = 0.278), hypertension (*p* = 0.521), dyslipidemia (*p* = 0.532) and smoking habit (*p* = 0.139). No correlation was found between EAT thickness and BMI (*r* = 0.02, *p* = 0.868).

Number and Type of Events {#S3.SS1}
-------------------------

After ICD implantation, all patients underwent 6-month follow up visits with a median follow-up period of 49.8 months \[range: 3.1--74.4 months\]. There were n. 30 HF related hospitalizations, and 5 HF related deaths. ICD check allowed to recognize n. 7 episodes of sustained atrial tachycardia, n. 20 episodes of atrial fibrillation lasting more than 30 s, n. 14 episodes of sustained ventricular tachycardia and 5 episodes of ventricular fibrillation. All arrhythmic ventricular events were succesfully treated by antitachycardia pacing and/or ICD shock therapy.

Predictors of Outcome {#S3.SS2}
---------------------

At univariate analysis, we tested the predictive value of the following variables: age, sex, BMI, diabetes, hypertension, smoking, NYHA class, LVEF, echocardiographic EAT thickness, HF ischaemic etiology, use of angiotensin-converting enzyme inhibitors or sartans and β-blockers. Using parsimonious criteria and taking into account the study sample size, 9 potentially prognostic independent variables have been selected for the multivariate analysis. The independent role of echocardiographic EAT thickness was assessed after adjusting each model for age, gender, BMI, diabetes, hypertension, smoking, LVEF and use of β-blockers.

### Composite Outcome {#S3.SS2.SSS1}

At univariate analysis, EAT was significantly associated with the outcome, showing, for each unit increase, a 16% increment in the hazard of the composite event \[H.R. 1.16; 95% C.I (1.08--1.24); *p* \< 0.001\]. A LVEF value below 35% determined about a two-fold increase in the hazard of the composite event \[H.R. 1.91; 95% C.I (1.08--3.37), *p* = 0.026\]. Of interest, at multivariate analysis, after adjusting for known risk factor, EAT remained significantly associated to the composite outcome while LVEF did not. When the analysis was repeated excluding atrial events, the results were almost the same; LVEF and EAT were both predictors of outcome at univariate analysis (*p* = 0.003 and *p* = 0.026 respectively), while only EAT remained a significant predictor at multivariate analysis (*p* = 0.008). BMI, diabetes and β-blockers were predictors of the composite outcome at the multivariate analysis ([Table 2](#T2){ref-type="table"}).

###### 

Predictors of the composite outcome.

                         **Composite outcome**                                
  ---------------------- ----------------------- ---------- ----------------- ----------
  Age (years)            1.01(0.98−1.04)         0.417      0.98(0.95−1.02)   0.386
  Gender; male           0.56(0.25−1.25)         0.156      0.46(0.18−1.23)   0.123
  NYHA class; III        1.16(0.65−2.08)         0.614      −                 −
  BMI (kg/m2)            0.93(0.87−0.99)         0.033      0.88(0.81−0.95)   0.002
  Diabetes               1.41(0.81−2.45)         0.221      2.01(1.05−3.82)   0.034
  Hypertension           0.94(0.53−1.67)         0.833      1.16(0.61−2.23)   0.651
  Smokers                1.6(0.6−1.87)           0.84       1.23(0.6−2.54)    0.572
  Ischemic cause of HF   1.01(0.56−1.82)         0.976      −                 −
  EAT thickness (mm)     1.16(1.08−1.24)         \< 0.001   1.18(1.09−1.27)   \< 0.001
  LVEF ≤ 35%             1.91(1.08−3.37)         0.026      1.59(0.82−3.08)   0.168
  Beta blockers          0.46(0.25−0.84)         0.012      0.46(0.23−0.91)   0.025
  ACE I/ARB              1.09(0.63−1.89)         0.763      −                 −

NYHA, New York heart association; BMI, body mass index; HF, heart failure; EAT, epicardial adipose tissue; LVEF, left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.

Heart failure related hospitalizations represented the outcome with the highest number of events. To rule out the possibility that hospitalization was the only trigger for the significance observed in the composite outcome, we excluded from this outcome the hospitalization and, again, the significant and independent role of EAT emerged \[HR: 1.12, 95% C.I (1.02--1.23), *p* = 0.021\].

### Arrhythmic Events {#S3.SS2.SSS2}

At univariate analysis, only EAT was associated with an increased risk of arrhythmic events with an HR equa1 to 1.12, \[95% C.I (1.03--1.22); *p* = 0.008\]. Even after adjusting for known risk factors, EAT remained a significant predictor with a 14% increase, for each unit increase, in the hazard of an arrhythmic event \[HR: 1.14; 95% C.I (1.03--1.25), *p* = 0.008\] ([Table 3](#T3){ref-type="table"}).

###### 

Predictors of the arrhythmic outcome.

                         **Arrhythmic outcome**                             
  ---------------------- ------------------------ ------- ----------------- -------
  Age (years)            1.02(0.98−1.06)          0.288   1(0.96−1.05)      0.891
  Gender; male           0.6(0.23−1.57)           0.301   0.86(0.26−2.82)   0.805
  NYHA class; III        1.34(0.66−2.72)          0.412   −                 −
  BMI (kg/m2)            092(0.85−1)              0.059   0.89(0.8−0.99)    0.025
  Diabetes               1.15(0.58−2.27)          0.692   1.61(0.73−3.57)   0.241
  Hypertension           0.74(0.37−1.49)          0.401   0.81(0.38−1.76)   0.599
  Smokers                0.94(0.47−1.87)          0.853   1.19(0.5−2.82)    0.694
  Ischemic cause of HF   0.83(0.41−1.67)          0.595   −                 −
  EAT thickness (mm)     1.12(1.03−1.22)          0.008   1.14(1.03−1.25)   0.011
  LVEF ≤ 35%             1.31(0.66−2.61)          0.445   0.96(0.43−2.13)   0.921
  Beta blockers          0.44(0.21−0.9)           0.025   0.47(0.21−1.02)   0.055
  ACE I/ARB              1.29(0.64−2.58)          0.476   −                 −

NYHA, New York heart association; BMI, body mass index; HF, heart failure; EAT, epicardial adipose tissue; LVEF, left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.

### Clinical Events {#S3.SS2.SSS3}

At univariate analysis, LVEF and EAT were both predictors of events \[HR: 2.43, 95% C.I (1.16--5.09), *p* = 0.018 and HR: 1.13, 95% C.I (1.03--1.23), *p* = 0.010; respectively\]. When both variables were considered in the same model adjusted for known risk factors, EAT remained the only significant predictor \[HR: 1.14, 95% C.I (1.03--1.27), *p* = 0.010\] ([Table 4](#T4){ref-type="table"}). A sensitivity analysis was performed to assess separately the predictive value of EAT on HF hospitalizations, the outcome with most frequent events. We found a significant and independent prognostic role of EAT, with a 13% increase in the hazard of hospitalization for every unit increase of EAT \[HR: 1.13, 95% C.I (1.01--1.26), *p* = 0.034\].

###### 

Predictors of the clinical outcome.

                         **Clinical outcome**                             
  ---------------------- ---------------------- ------- ----------------- -------
  Age (years)            0.99(0.96−1.03)        0.722   0.97(0.93−1.02)   0.201
  Gender; male           0.84(0.29−2.43)        0.754   0.43(0.11−1.71)   0.229
  NYHA class; III        1.07(0.51−2.26)        0.861   −                 −
  BMI (kg/m2)            0.94(0.86−1.02)        0.148   0.9(0.79−1.02)    0.105
  Diabetes               1.81(0.89−3.68)        0.104   2.2(0.97−4.97)    0.059
  Hypertension           1.67(0.75−3.73)        0.209   2.56(1−6.53)      0.05
  Smokers                1.14(0.55−2.35)        0.727   1.11(0.44−2.82)   0.827
  Ischemic cause of HF   1.56(0.67−3.61)        0.299   −                 −
  EAT thickness (mm)     1.13(1.03−1.23)        0.01    1.14(1.03−1.27)   0.011
  LVEF ≤ 35%             2.43(1.16−5.09)        0.018   2.28(1−5.22)      0.051
  Beta blockers          0.95(0.41−2.2)         0.898   1.06(0.42−2.71)   0.896
  ACE I/ARB              0.79(0.39−1.57)        0.495   −                 −

NYHA, New York Heart Association; BMI, body mass index; HF, heart failure; EAT, epicardial adipose tissue; LVEF, left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.

Kaplan Meiers estimates of the probability of remaining events free for each of the three considered outcomes and stratified according to EAT median value are shown in [Figure 2](#F2){ref-type="fig"}.

![Kaplan Meiers curves illustrating the probability of remaining events free for each of the three considered outcomes \[panel **(A)** composite outcome; panel **(B)** arrhythmic outcome; panel **(C)** clinical outcome\] and stratified according to EAT median value. EAT, epicardial adipose tissue.](fphys-11-00043-g002){#F2}

Discussion {#S4}
==========

The main finding of the present study is that echocardiographic measurement of EAT predicts outcome in high risk HF patients. In particular, EAT is associated with both arrhythmic and clinical events.

Epicardial adipose tissue represents the visceral fat depot of the heart which covers 80% of the heart's surface ([@B15]). In pathologic conditions, EAT may play an unfavorable activity for the heart through production and secretion of proinflammatory and proatherogenic mediators ([@B4]) and is associated with atherosclerotic diseases, such as coronary artery disease, and aortic stenosis ([@B6]; [@B8]; [@B25], [@B23]; [@B19]). Local levels of EAT-secreted inflammatory mediators are higher than those observed in the subcutaneous adipose tissue and are independent from the presence of obesity, and diabetes ([@B21]). EAT obtained from patients with coronary artery disease shows a greater inflammatory infiltrate compared to subcutaneous adipose tissue and activation of both innate and adaptive immunity ([@B21]; [@B3]). Moreover, human EAT shows higher mRNA expression of proteins involved in oxidative stress ([@B29]). Oxidative stress and the specific regulation of signaling pathways by reactive oxygen species (ROS) are increasingly recognized as important contributors to the pathophysiology of HF, influencing many key aspects of the failing heart phenotype such as hypertrophy, matrix remodeling, contractile dysfunction, endothelial dysfunction, and arrhythmias ([@B13]). There is a growing body of evidence that immune activation and inflammation play a crucial role in the progression of LV dysfunction ([@B14]; [@B34]). Thus, it seems to be reasonable to hypothesize that EAT, through its potent pro-atherogenic, pro-inflammatory, pro-oxidant activities, may contribute to HF pathogenesis and influence the progression of LV dysfunction in HF patients.

Epicardial adipose tissue is associated with LV hypertrophy and diastolic dysfunction ([@B16]; [@B10]). Importantly, it has been demonstrated that human EAT can induce myocardial fibrosis through secretion of adipofibrokines, such as Activin A ([@B33]). In this regard, it is known that myocardial fibrosis represents an important pathophysiological mechanism involved in HF development and progression ([@B30]; [@B11]) and it may be a trigger for both atrial and ventricular arrhythmias ([@B12]; [@B27]). Therefore, EAT could contribute to the formation of an unfavorable pro-arrhythmic substrate conditioning HF adverse prognosis. The pro-arrhythmic activity of EAT could be also explained by its contribution to enhance the adrenergic nervous system derangement in HF. We have previously demonstrated that EAT is a local source of catecholamines and its echocardiographic thickness is associated to myocardial adrenergic denervation at ^123*I--*^metaiodobenzylguanidine scintigraphy ([@B26]), one of the most powerful imaging technique to assess HF prognosis ([@B17]). Furthermore, it has been demonstrated that EAT contains both adrenergic and cholinergic nerves which interact with the extrinsic nervous system ([@B2]; [@B7]). Simultaneous activation of these nerve structures within EAT in response to extrinsic nerve activation may enhance triggered activity and facilitate the development of cardiac arrhythmias ([@B9]; [@B35]; [@B18]). Overall, these findings strongly support the EAT involvement in the pathophysiological processes affecting HF prognosis.

In the present study, we have reported, for the first time, that the simple echocardiographic measurement of EAT may be helpful to predict HF prognosis. We measured EAT at the Rindfleisch fold, a pericardial recess between the right ventricle and the aorta, where EAT measurement shows excellent reproducibility and well correlates with cardiac magnetic resonance EAT thickness and volume ([@B24]). At this level, the downward curvature of the right ventricle increases the space between the two pericardial layers, thus allowing the EAT expansion, its visualization and accurate measurement.

The population of this study was composed of HF patients enrolled at the time of ICD implantation for primary and secondary prevention. In this population, EAT thickness was independently associated with both clinical and arrhythmic outcomes. Importantly, EAT showed, for each unitary increase, a 16% increment in the hazard of the composite outcome and a 14% increment in the hazard of the arrhythmic outcome, thus confirming a powerful prognostic value in HF population. Regarding the unexpected lack of significance of LVEF on the different outcomes at multivariate analysis, we can only speculate that it might be ascribed to two distinct factors: (1) the capture of LVEF effect by the higher prognostic impact of EAT in the model; (2) the wide distribution of LVEF in the study population due to the inclusion of patients referred to ICD implantation in secondary prevention, thus showing, in many cases, a LVEF higher than 35%.

Study Limitations {#S4.SS1}
-----------------

The major study limitation of the present study is represented by the relatively small sample size. However, we are confident that the results should not have been biased because of the small sample size. In fact, an insufficient sample size should move the results toward the null (i.e., no significant effect) rather than toward the alternative hypothesis. We are, at the same time, aware of the risk of inflating the probability of type I error due to the number of statistical models we used but, due to the consistency of the results for the different outcomes, we believe in their plausibility.

Our study population included patients with different HF etiologies (ischemic and non-ischemic) and with a skewed distribution of LVEF values. This might explain the lack of a significant prognostic impact of LVEF on the different outcomes considered.

The small sample size and the risk of increasing the probability of type-2 error, did not allowed us to separately analyze each of the outcomes considered. Notewhorthy, the number of deaths was very low, probably due to the selection of the study population (no patient died for sudden cardiac death given the ICD shock), thus avoiding to consider cardiac deaths as a separate outcome.

The main finding of the study is that EAT thickness is an independent predictor of outcome at multivariate analysis. This finding is highly novel and proposes EAT for HF risk stratification. However, larger studies are required to confirm our preliminary data and to assess the superiority of EAT thickness over other established markers of HF prognosis.

Conclusion {#S5}
==========

The results of the present study suggest a potential role of echocardiographic EAT assessment in predicting clinical and arrhythmic outcomes in HF patients referred to ICD implantation for primary and secondary prevention. The pathophysiologic explanation of the association of EAT accumulation with HF prognosis relies in the pathologic properties of EAT able to promote cardiac fibrosis and adrenergic derangement that represent two important determinants of HF progression and contribute to the development of a pro-arrhythmic substrate.

To date, the selection of candidates to ICD implantation in primary prevention is still based on echocardiographic LVEF estimation. Nevertheless, only one third of ICD recipients with LVEF ≤35% receives appropriate therapy ([@B5]; [@B31]), thus, we dramatically needed of novel markers, with higher sensitivity and specificity, for a better recognition of those HF patients who will really benefit from ICD therapy.

Given the recognized correlation of EAT with cardiac adrenergic denervation, a powerful indicator of worse HF prognosis, it seems to be reasonable to hypothesize that the echocardiographic assessment of cardiac visceral fat could represent, in the next future, a promising diagnostic tool to improve the HF risk stratification and the appropriateness of HF therapies.
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